| 8.75 -0.29 (-3.21%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.93  |
1-year : | 13.12 |
| Resists | First : | 10.22 |
Second : | 11.23 |
| Pivot price | 9.89 |
|||
| Supports | First : | 8.56 |
Second : | 7.13 |
| MAs | MA(5) : | 9.17 |
MA(20) : | 10.06 |
| MA(100) : | 11.43 |
MA(250) : | 16.07 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 10 |
D(3) : | 10 |
| RSI | RSI(14): 30.7 |
|||
| 52-week | High : | 36.25 | Low : | 6.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OLMA ] has closed above bottom band by 6.2%. Bollinger Bands are 0.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.06 - 9.11 | 9.11 - 9.14 |
| Low: | 8.45 - 8.51 | 8.51 - 8.56 |
| Close: | 8.67 - 8.76 | 8.76 - 8.83 |
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Wed, 23 Sep 2026
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.1% - Time to Sell? - MarketBeat
Wed, 16 Sep 2026
Olema Pharmaceuticals (OLMA) Slips to $9.75 as Shares Sit Mid-Range Between Key Levels - Gamma Squeeze - careplusvn.com
Wed, 09 Sep 2026
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Wed, 09 Sep 2026
Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1'27 (NASDAQ:OLMA) - Seeking Alpha
Wed, 02 Sep 2026
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036 - stocktitan.net
Wed, 02 Sep 2026
A new finance chief gets options on 650,000 Olema shares - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 119.5 (%) |
| Shares Short | 15,810 (K) |
| Shares Short P.Month | 15,100 (K) |
| EPS | -2.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.9 % |
| Return on Equity (ttm) | -52.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -165 (M) |
| Levered Free Cash Flow | -89 (M) |
| PE Ratio | -4.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|